Reportlinker.com

Reportlinker.com

June 23, 2008 15:43 ET

Learn about the Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments

LONDON, UNITED KINGDOM--(Marketwire - June 23, 2008) - Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments

http://www.reportlinker.com/p090379/Leading-Drug-Delivery-Companies-and-Technologies-Competitive-landscape-company-profiles-and-technological-developments.html

Leading Drug Delivery Companies and Technologies

Competitive landscape, company profiles and technological developments

Business Intelligence for the Pharmaceutical Industry

Business Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions.

The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry.

Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.

Some key findings from this report...

The oral delivery system continues to dominate the drug delivery market due to convenient usage, cost-effectiveness and low frequency of administration. Needleless injectables, PEGylation technologies and micro-electromechanical devices are among the novel technologies with the greatest growth potential.

The market for parenteral drugs and solutions sold in prefilled syringes and premixed IV systems will grow, due to the ease of administration and resistance to infections associated with these methods. The needle-free delivery sector will rise to $3bn by 2010.

Pulmonary delivery technologies are increasingly prevalent in pain management, cystic fibrosis and diabetes. Pulmonary-based delivery vehicles are currently the focus of a number of major companies including Nektar, Aradigm, 3M, and Alkermes.

Dry powder inhalers will secure the largest share of sales within the asthma market, as demand for treatments in this therapy area continues to expand. However, MDI products will experience a relatively higher rate of growth due to consistent improvements in particle size and safe propellant delivery.

Leading Drug Delivery Companies and Technologies

Over the last decade, the drug delivery industry has evolved to become a key area in the development of value-added pharmaceutical products. The global market grew from $15bn to $40bn during 2000-2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues. Although the market is still dominated by the oral drug delivery system, a number of novel technologies are emerging across all systems of delivery. However, the pure drug delivery company model is rapidly becoming extinct as leading players attempt to consolidate their strategic opportunities by expanding their focus towards manufacturing, a trend that is expected to accelerate over the next five years.

'Leading Drug Delivery Companies and Technologies' is a new report published by Business Insights that examines the current and future trends that are shaping the drug delivery market and reviews the key emerging technologies across major systems of drug delivery. This report identifies the product portfolios and targeted therapeutic areas of leading drug delivery companies in addition to assessing their technology platforms to provide guidance over their applicability, regulatory implications and developmental progress. This report also evaluates the opportunities and threats facing each of the companies profiled and provides a comparative analysis of the growth strategies used to facilitate successful deals and collaborations.

Identify key trends and developments in the global drug delivery market, assess the performances and portfolios of leading drug delivery companies and benchmark their strategies with this new report...

Top reasons to order your copy today

- Discover the key issues and trends in the global drug delivery market with this report's analysis of market size and growth, the commercial value of drug delivery systems and the extended strategic focus of growing numbers of drug delivery companies.

- Identify the dynamics of major drug delivery systems by evaluating the latest market developments and technological innovations in oral, pulmonary, injectable and transdermal delivery platforms.

- Assess the leading players in the drug delivery market with this report's review of the opportunities and threats, financial performances and R&D expenditures of Biovail, Elan, SkyePharma, Alkermes, Bioject, QLT, Nektar, Aradigm, Antares, Noven, Alza and 3M.

- Benchmark the strategies of leading drug delivery companies by evaluating their product portfolios and pipelines, deals and alliances, targeted therapeutic areas and technology platforms

Key issues examined in this report...

- Technology driving growth. Drug delivery technologies are being used to boost revenues and enhance product efficacy by developing future commercial opportunities and expanding product lifecycles.

- Expanding strategic focus. A growing number of drug delivery companies are evolving into specialty pharma companies. Widening the core business to incorporate manufacturing is a strategy increasingly used to enhance revenues.

- Stagnant R&D investment. The companies featured in this report recorded an average growth in R&D expenditure of just 6% during 2003-2007. This low growth in R&D spend is likely to inhibit the discovery and development of new products in the short term.

- Inhaled insulin setback. The development of inhaled insulin has been the focus of many companies operating in the pulmonary drug delivery field. However, a high number late-stage terminations have raised doubts over the commercial potential of this delivery vehicle.

Your questions answered...

- What are the major issues surrounding drug delivery within the global pharma industry?

- What are the latest innovations and developments in different drug delivery vehicles?

- What are the market dynamics for oral, injectable, pulmonary and transdermal drug delivery systems?

- What are the key technologies and growth strategies of leading drug delivery companies?

- What are the product portfolios, pipeline candidates, financial performances and R&D expenditures of these leading companies?

- What opportunities and threats will drug delivery companies face in the future?

Table of Contents

Leading Drug Delivery Companies and Technologies

Executive Summary 12

Overview on drug delivery industry 12

Oral drug delivery system 12

Injectable drug delivery system 13

Pulmonary drug delivery system 14

Transdermal drug delivery system 15

Chapter 1 Overview of drug delivery

industry 18

Summary 18

What is this report about? 19

Methodology 20

Drug delivery overview 21

Role of drug delivery in the pharma landscape 21

Revenue boosters for pharma companies 22

Patent extension and protection from generic competition 23

Reformulation of existing products 24

Optimizing returns on R&D investment 25

Compliance, bioavailability and safety benefits 26

From drug delivery to specialty pharma 28

Markets for drug delivery systems 30

Oral drug delivery system 30

Pulmonary 30

Injectable 30

Transdermal 30

Market dynamics 31

Chapter 2 Oral drug delivery system 34

Summary 34

Synopsis 35

Oral drug delivery technologies 35

Technologies for fast-dissolving and taste-masking pills 35

Controlled oral drug delivery 36

Types of controlled release 36

Dynamics of oral drug delivery market 37

Biovail 39

Key technologies 39

Therapeutic focus 41

Product portfolio and pipeline candidates 41

Recent financial performance 42

Growth strategies 44

Expanding its presence in diverse geographical areas 44

Deriving growth from strategic alliances 44

Deals and alliances 44

SWOT analysis 45

Strengths 46

Weaknesses 46

Opportunities 47

Threats 47

Elan 48

Key technologies 48

NanoCrystal technology 48

OCR technology 49

Therapeutic focus 50

Product portfolio and pipeline candidates 51

Recent financial performance 52

Growth strategies 54

Alzheimer's disease 54

Pipeline products 54

Deals and alliances 54

SWOT analysis 56

Strengths 56

Weaknesses 57

Opportunities 57

Threats 58

SkyePharma 59

Key technologies 59

Oral drug delivery technologies 59

Inhalation technologies 60

Insoluble drug delivery (IDD) technology 61

Therapeutic focus 62

Products portfolio and pipeline candidates 62

Recent financial performance 63

Growth strategies 65

Focus on building pipeline of products 65

Deals and alliances 66

SWOT analysis 67

Strengths 67

Weaknesses 68

Opportunities 68

Threats 69

Chapter 3 Injectable drug delivery system 72

Summary 72

Synopsis 73

Injectable drug delivery technologies 73

Needleless injection device technology 74

Sustained/controlled release technology 74

PEGylation 74

Therapeutic focus 75

Dynamics of the injectable drug delivery market 75

Alkermes 76

Introduction 76

Key technologies 76

Medisorb injectable technology 76

AIR pulmonary drug delivery technology 77

Therapeutic focus 77

Product portfolio and pipeline candidates 77

Recent financial performance 78

Growth strategies 80

Deals and alliances 81

SWOT analysis 82

Strengths 82

Weaknesses 83

Opportunities 83

Threats 83

Bioject 85

Introduction 85

Key technologies 85

Needle-free injection technology 85

Therapeutic Focus 86

Product portfolio and pipeline candidates 86

Recent financial performance 87

Growth strategies 89

Developing clinical research collaborations 89

Deals and alliances 90

SWOT analysis 91

Strengths 91

Weaknesses 91

Opportunities 92

Threats 92

QLT 93

Key technologies 93

Atrigel drug delivery system 93

PDT 94

Therapeutic focus 94

Product portfolio and pipeline candidates 94

Recent company financials 95

Growth strategies 97

Focus on key therapeutic areas 97

Deals and alliances 98

SWOT analysis 99

Strengths 99

Weaknesses 100

Opportunities 100

Threats 101

Chapter 4 Pulmonary drug delivery system 104

Summary 104

Synopsis 105

Inhaled formulations 105

Therapeutic focus 106

Dynamics of the pulmonary drug delivery market 107

Nektar Therapeutics 108

Key technologies 108

Dry powder pulmonary technology 108

Liquid pulmonary technology 109

PEGylation technology 109

Therapeutic focus 109

Product portfolio and pipeline candidates 110

Recent financial performance 111

Growth strategies 112

Shifting focus from drug delivery to become a specialty pharma

company 113

Deals and alliances 113

SWOT analysis 114

Strengths 114

Weaknesses 115

Opportunities 115

Threats 116

Aradigm 118

Key technologies 118

AERx pulmonary drug delivery system 118

Liposomal Formulations 119

Therapeutic focus 119

Product portfolio and pipeline candidates 119

Recent financial performance 120

Growth strategies 122

Deals and alliances 122

SWOT analysis 123

Strengths 123

Weaknesses 123

Opportunities 124

Threats 124

3M 125

Key technologies 125

Pulmonary drug delivery technology 125

Transdermal drug delivery technology 126

Therapeutic focus 126

Product portfolio and pipeline candidates 127

Growth strategies 127

Deals and alliances 128

Chapter 5 Transdermal drug delivery system 132

Summary 132

Synopsis 133

Transdermal drug delivery technologies 133

Passive formulations 134

Active formulations 134

Therapeutic focus 135

Dynamics of the transdermal drug delivery market 135

Antares 137

Key technologies 137

Advanced transdermal delivery 137

Injection devices 138

Easy Tec fast melt oral disintegrating tablets 139

Therapeutic focus 139

Product portfolio and pipeline candidates 139

Recent financial performance 140

Growth strategies 142

Deals and alliances 143

SWOT analysis 145

Strengths 145

Weaknesses 146

Opportunities 147

Threats 148

Noven 150

Key technologies 150

DOT Matrix technology 150

Therapeutic focus 151

Product portfolio and pipeline candidates 152

Recent financial performance 153

Growth strategies 154

Deals and alliances 155

SWOT analysis 155

Strengths 155

Weaknesses 157

Opportunities 158

Threats 158

Alza 159

Key technologies 159

D-Trans 159

E-Trans 160

Macroflux 160

Stealth 160

Alzamer 161

Oros 161

Therapeutic focus 162

Product portfolio and pipeline candidate 162

Deals and alliances 163

SWOT analysis 164

Strengths 164

Weaknesses 165

Opportunities 166

Threats 166

Chapter 6 Conclusion 168

Financials 168

Growth strategies 169

Outlook 172

Glossary 174

Index 175

List of Figures

Figure 1.1: Drug delivery technologies are revenue boosters for pharma companies 22

Figure 1.2: Procardia XL patent expiry 23

Figure 1.3: Cardizem's reformulation strategy 25

Figure 1.4: Compliance, bioavailability and safety benefits via effectice drug delivery 27

Figure 1.5: Positioning of key drug delivery companies 29

Figure 1.6: Key drug delivery systems market share, 2006 31

Figure 2.7: Biovail financial performance, $m, 2003-2007 43

Figure 2.8: Biovail SWOT analysis 45

Figure 2.9: Elan financial performance, 2003-2007 ($m) 53

Figure 2.10: Elan SWOT analysis 56

Figure 2.11: SkyePharma financial performance, $m, 2003-2007 65

Figure 2.12: SkyePharma SWOT analysis 67

Figure 3.13: Alkermes financial performance, 2003-2007 80

Figure 3.14: Alkermes SWOT analysis 82

Figure 3.15: Bioject financial performance, 2003-2007 ($m) 89

Figure 3.16: Bioject SWOT analysis 91

Figure 3.17: QLT financial performance, 2003-2007 ($m) 97

Figure 3.18: QLT SWOT analysis 99

Figure 4.19: Nektar financial performance, 2003-2007 ($m) 112

Figure 4.20: Nektar SWOT analysis 114

Figure 4.21: Aradigm financial performance, 2003-2007 ($m) 121

Figure 4.22: Aradigm SWOT analysis 123

Figure 5.23: Antares financial performance, 2003-2007 ($m) 142

Figure 5.24: Antares SWOT analysis 145

Figure 5.25: Noven financial performance, 2003-2007 ($m) 154

Figure 5.26: Noven SWOT analysis 155

Figure 5.27: Alza SWOT analysis 164

Figure 6.28: Comparative analysis of key drug delivery companies (I) 170

Figure 6.29: Comparative analysis of key drug delivery companies (II) 171

List of Tables

Table 2.1: Biovail snapshot 39

Table 2.2: Biovail oral marketed products 41

Table 2.3: Biovail oral product sales, 2006-2007 ($m) 41

Table 2.4: Biovail oral product pipeline 42

Table 2.5: Biovail financial performance, 2003-2007 ($m) 43

Table 2.6: Elan snapshot 48

Table 2.7: Elan oral marketed products 51

Table 2.8: Elan NanoCrystal product pipeline 52

Table 2.9: Elan financial performance, 2003-2007 ($m) 53

Table 2.10: SkyePharma snapshot 59

Table 2.11: SkyePharma oral marketed products 62

Table 2.12: Skye Pharma oral product pipeline 63

Table 2.13: SkyePharma financial performance, 2003-2007 64

Table 3.14: Alkermes snapshot 76

Table 3.15: Alkermes injectable marketed products 78

Table 3.16: Alkermes injectable product sales, 2006-2007 ($m) 78

Table 3.17: Alkermes injectable product pipeline 78

Table 3.18: Alkermes financial performance, 2003-2007 ($m) 79

Table 3.19: Bioject snapshot 85

Table 3.20: Bioject injectable marketed products 86

Table 3.21: Bioject injectable product sales, 2006-2007 ($m) 87

Table 3.22: Bioject financial performance, 2003-2007 ($m) 88

Table 3.23: QLT snapshot 93

Table 3.24: QLT injectable marketed products 95

Table 3.25: QLT injectable product sales, 2006-2007 ($m) 95

Table 3.26: QLT injectable product pipeline 95

Table 3.27: QLT financial performance, 2003-2007 ($m) 96

Table 4.28: Nektar snapshot 108

Table 4.29: Nektar pulmonary marketed products 110

Table 4.30: Nektar pulmonary product sales, 2006-2007 ($m) 110

Table 4.31: Nektar pulmonary product pipeline 111

Table 4.32: Nektar financial performance, 2003-2007 ($m) 112

Table 4.33: Aradigm snapshot 118

Table 4.34: Aradigm pulmonary product pipeline 120

Table 4.35: Aradigm financial performance, 2003-2007 ($m) 121

Table 4.36: 3M snapshot 125

Table 4.37: 3M pulmonary marketed products 127

Table 5.38: Antares snapshot 137

Table 5.39: Antares transdermal marketed products 139

Table 5.40: Antares transdermal product pipleine 140

Table 5.41: Antares financial performance, 2003-2007 ($m) 141

Table 5.42: Noven snapshot 150

Table 5.43: Noven transdermal marketed products 152

Table 5.44: Noven transdermal product pipeline 152

Table 5.45: Noven financial performance, 2003-2007 ($m) 153

Table 5.46: Alza snapshot 159

Table 5.47: Alza transdermal marketed products 162

To order this report:

Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments

http://www.reportlinker.com/p090379/Leading-Drug-Delivery-Companies-and-Technologies-Competitive-landscape-company-profiles-and-technological-developments.html

More market research reports here!

Contact Information